Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) saw an uptick in trading volume on Wednesday . 2,429,553 shares traded hands during mid-day trading, a decline of 12% from the previous session’s volume of 2,755,380 shares.The stock last traded at $2.20 and had previously closed at $2.12.
A number of brokerages recently issued reports on AEZS. Maxim Group set a $2.00 price objective on shares of AEterna Zentaris and gave the company a “buy” rating in a research note on Saturday, July 1st. Zacks Investment Research raised shares of AEterna Zentaris from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. HC Wainwright set a $3.00 price objective on shares of AEterna Zentaris and gave the company a “buy” rating in a research note on Wednesday, July 5th. Finally, ValuEngine raised shares of AEterna Zentaris from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. AEterna Zentaris presently has an average rating of “Hold” and an average price target of $4.33.
The stock’s market cap is $35.44 million. The stock’s 50-day moving average price is $2.00 and its 200 day moving average price is $1.78.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.05). AEterna Zentaris had a negative return on equity of 514.64% and a negative net margin of 1,945.78%. The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.22 million. The company’s revenue was up 153.1% on a year-over-year basis. Equities analysts anticipate that AEterna Zentaris Inc. will post ($1.02) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.themarketsdaily.com/2017/10/11/aeterna-zentaris-inc-aezs-sees-large-volume-increase.html.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.